<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811133</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19100221</org_study_id>
    <nct_id>NCT02811133</nct_id>
  </id_info>
  <brief_title>Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder</brief_title>
  <official_title>Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ronald M. Glick, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Fine Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jarrow Formulas Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open trial that seeks to determine the safety and tolerability of using inositol
      for children and adolescents with bipolar disorder and comorbid anxiety disorders with an
      exploration of efficacy and dose-response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety disorders are common comorbidities among children and adolescents with bipolar
      disorder. Treatment with standard pharmacologic agents may worsen mood problems or lead to
      drug dependency. Inositol has shown benefits for bipolar depression in adults. This is an
      open multi-case control study. The investigators will enroll 20 children and adolescents ages
      8-17 treated at the Child and Adolescent Bipolar Services (CABS) at Western Psychiatric
      Institute and Clinic. Participants' involvement will be 14 weeks, including the initial
      titration of the supplement, maintenance, and taper. Primary outcomes will include standard
      measures of mood and anxiety. Also, physiologic measures including body mass index and
      bedside glucose will be followed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the safety of myo-inositol, anxiety and mood symptoms will be measured using Clinical Global Impression Severity (CGI-S).</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>This assessment rates the clinician's view of the patient's anxiety severity prior to and after initiating myo-inositol. Scores range from 0-7. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the safety of myo-inositol, anxiety and mood symptoms will be measured using the Patient Global Index of Change Severity (PGIC-S).</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>This scale is a parent and child report tool that evaluates participants' anxiety and assesses if there has been a decline in clinical status. Answer options are &quot;0-None&quot;, &quot;1-Mild&quot;, &quot;2-Moderate&quot;, and &quot;3-Severe&quot; and describe symptoms of anxiety. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the tolerability of myo-inositol, the number of participants who are able to remain on myo-inositol for the full treatment period (10-12 weeks) will be measured.</measure>
    <time_frame>Weeks 1-14</time_frame>
    <description>At study completion, the number of participants who remained on myo-inositol for the full 10-12 weeks will be counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the tolerability of myo-inositol, the number of participants able to remain on the full dosage of myo-inositol for the full treatment period (10-12 weeks) will be measured.</measure>
    <time_frame>Weeks 3-8</time_frame>
    <description>Participants will be titrated up to the full dose of myo-inositol by Week 3 and will remain on the full dose for 6 weeks unless they cannot tolerate the dose. At study completion, the number of participants who remained on the full-dose of myo-inositol for the full 10-12 weeks will be counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the safety and tolerability of myo-inositol, a change from baseline on the Physical Symptom Checklist (Side Effect Rating Scale) will be measured.</measure>
    <time_frame>Weeks 1-14</time_frame>
    <description>This assessment is a parent and child report measure. Its scores range from 0 to 60. Higher scores are indicative of more physical and psychological symptoms and worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the safety of myo-inositol, the Brief Suicide Severity Rating Scale (B-SSRS) will be measured at each visit.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>The B-SSRS probes for suicidal thoughts and behavior. The scores for both categories range from 0-5. If participants score greater than 1 on B-SSRS ideation or greater than 0 on B-SSRS behavior, then they cannot be enrolled or remain in the study. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the safety of myo-inositol, a fingerstick blood test will be done to measure glucose levels at the first and final study visits.</measure>
    <time_frame>Week 1 &amp; Week 10-12</time_frame>
    <description>A glucometer will be used to test the blood glucose levels of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the safety of myo-inositol, physical measurements (height and weight) will be obtained.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Myo-inositol is dosed by the weight of the participant. To make sure the participant is taking the correct dose, weight will be measured at each study visit. Height will only be measured at Week 1 to calculate BMI. Also, change in weight or BMI will be followed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for mood symptoms, a change from baseline on the Moods and Feelings Questionnaire (MFQ) will be evaluated.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>The Mood and Feelings Questionnaire (MFQ) is a child and parent report questionnaire that measures depressive symptoms in children and young adults. Scores range from 0 to 66. Higher score are indicative of increased depressive symptom severity and worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on Clinical Global Impression Improvement (CGI-I) will be evaluated.</measure>
    <time_frame>Weeks 2-12</time_frame>
    <description>This assessment rates the clinician's view of the patient's anxiety improvement after initiating myo-inositol. Scores range from 0-7. Higher scores mean worse anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on Clinical Global Impression Severity (CGI-S) will be evaluated.</measure>
    <time_frame>Weeks 2-12</time_frame>
    <description>This assessment rates the clinician's view of the patient's anxiety severity before and after initiating myo-inositol. Scores range from 0-7. Higher scores mean more anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on Brief Child Mania Rating Scale Parent Version (BCMRS-P) will be evaluated.</measure>
    <time_frame>Week 1 &amp; Weeks 10-12</time_frame>
    <description>The BMRS-P is a 10-item inventory rated on a 4 point Likert type scale anchored by 0 (never/rare), 1 (sometimes), 2 (often), and 3 (very often). Its purpose is to measure changes in symptoms of pediatric bipolar disorder (PBD) as they change over time. Scores range from 0 to 30. Higher scores mean more symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on the Patient Global Index of Change Improvement (PGIC-I) will be evaluated.</measure>
    <time_frame>Weeks 2-12</time_frame>
    <description>This scale evaluates participants' anxiety and assesses if there has been an improvement in clinical status. Answer options are &quot;Much Improved&quot;, &quot;Minimally Improved&quot;, &quot;No Change&quot;, &quot;Minimally Worse&quot;, and &quot;Much Worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on the Patient Global Index of Change Severity (PGIC-S) will be evaluated.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>This scale is a child and parent self-report instrument used to evaluate participants' anxiety and assesses if there has been a decline in clinical status. Answer options are &quot;0-None&quot;, &quot;1-Mild&quot;, &quot;2-Moderate&quot;, and &quot;3-Severe&quot; and describe symptoms of anxiety. Higher scores mean more anxiety symptoms and worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on the Self-Report for Childhood Related Emotional Disorders (SCARED) will be evaluated.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>The SCARED is a child and parent self-report instrument used to screen for childhood anxiety disorders including general anxiety disorder, separation anxiety disorder, panic disorder, and social phobia. The SCARED consists of 41 items and 5 factors that parallel the DSM-IV classification of anxiety disorders. Scores range from 0-82. Scores greater than or equal to 25 indicate the presence of an anxiety disorder and scores in different items indicate the type of anxiety disorder.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Inositol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive inositol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inositol</intervention_name>
    <description>Subjects will receive inositol</description>
    <arm_group_label>Inositol</arm_group_label>
    <other_name>Myoinositol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Evidence in the medical record confirming the DSM-V diagnosis of bipolar disorder. If
             this documentation is not in the record, then the appropriate sections of K-SADS will
             be administered to confirm the diagnosis.

          2. Evidence in the medical record confirming the DSM-V diagnosis of anxiety disorder
             including; separation anxiety disorder, generalized anxiety disorder, and/or social
             phobia. If this documentation is not present or is more than 2 years old, then the
             appropriate section of the K-SADS will be administered to confirm diagnosis.

          3. At least moderate severity of anxiety symptoms as determined by score of â‰¥ 13 on the
             Pediatric Anxiety Rating Scale (PARS).

          4. On a stable dose of psychotropic medications for at least one month, with no major
             changes projected.

        Exclusion Criteria:

          1. Presence of prominent diarrhea.

          2. Diagnosis of diabetes mellitus.

          3. Presence of active suicidal ideation and behavior or psychosis. B-SSRS ideation score
             greater than 1. B-SSRS behavior score greater than 0.

          4. Weight less than 20 kg.

          5. Known pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Glick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine McFarland</last_name>
    <phone>412-623-6872</phone>
    <email>mcfarlandce@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald Glick, MD</last_name>
    <phone>412-623-3023</phone>
    <email>glickrm@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Child and Adolescent Bipolar Services-WPIC Bellefield</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH. Inositol treatment in psychiatry. Psychopharmacol Bull. 1995;31(1):167-75. Review.</citation>
    <PMID>7675981</PMID>
  </reference>
  <reference>
    <citation>Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry. 1995 Jul;152(7):1084-6.</citation>
    <PMID>7793450</PMID>
  </reference>
  <reference>
    <citation>Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord. 2006 Apr;8(2):168-74.</citation>
    <PMID>16542187</PMID>
  </reference>
  <reference>
    <citation>Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996 Sep;153(9):1219-21.</citation>
    <PMID>8780431</PMID>
  </reference>
  <reference>
    <citation>Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997 May;7(2):147-55.</citation>
    <PMID>9169302</PMID>
  </reference>
  <reference>
    <citation>Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995 May;152(5):792-4.</citation>
    <PMID>7726322</PMID>
  </reference>
  <reference>
    <citation>Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001 Jun;21(3):335-9.</citation>
    <PMID>11386498</PMID>
  </reference>
  <reference>
    <citation>Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 2005 Feb;7(1):1-10. Review.</citation>
    <PMID>15654927</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ronald M. Glick, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>inositol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon request from other researchers, we will make available de-identified subject data, as appropriate.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be shared, as deemed appropriate, starting 6 months after completion of the study for a period of 5 years.</ipd_time_frame>
    <ipd_access_criteria>Biomedical researcher involved in research activity in a related field and from an established research institution.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

